

## **Supplementary Appendix**

### **Study design**

This non-interventional study was conducted between March 19, 2020 and April 3, 2020 in Cochin Hospital (Paris, France), in the setting of the local RADIPEM biological samples collection derived from samples collected in routine care. Biological collection and informed consent were approved by the Direction de la Recherche Clinique et Innovation (DRCI) and the French Ministry of Health. Inclusion criteria for COVID-19 inpatients were: age between 18 and 80 years old, diagnosis of COVID-19 according to WHO interim guidance, and positive SARS-CoV-2 RT-PCR testing on a respiratory sample (nasopharyngeal swab or invasive respiratory sample). Inpatients with pre-existing unstable chronic disorders (such as uncontrolled diabetes mellitus, severe obesity defined as body mass index greater than 30, unstable chronic respiratory disease or chronic heart disease) were excluded. Since median duration from onset of symptoms to respiratory failure was previously shown to be 9.5 (interquartile range, 7.0-12.5) days<sup>1</sup>, we analyzed immune signatures between 8 to 12 days after first symptoms for all patients and before the initiation of any antiviral or anti-inflammatory treatment. Healthy controls were asymptomatic adults, matched with cases on age, with a negative SARS-CoV-2 RT-PCR testing at time of inclusion. The study conforms to the principles outlined in the Declaration of Helsinki.

Epidemiological, demographic, clinical, laboratory, treatment, and outcome data were extracted from electronic medical records using a standardized data collection form. Routine blood examinations were complete blood count, plasmatic biochemical tests (including renal and liver function, lactate dehydrogenase (LDH), and electrolytes), C-

reactive protein (CRP), plasmatic interleukin-6 (IL-6) and ferritin. Chest radiographs or CT scan were also done for all inpatients.

Laboratory confirmation of SARS-CoV-2 was performed at the Cochin Hospital, Virology Department, Paris, France. RT-PCR assays were performed in accordance with the protocol established by the WHO (World Health Organization. Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans (<https://www-who-int.proxy.insermbiblio.inist.fr/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance>)).

The severity of COVID-19 was classified based on the adaptation of the Sixth Revised Trial Version of the Novel Coronavirus Pneumonia Diagnosis and Treatment Guidance. Mild cases were defined as mild clinical symptoms (fever, myalgia, fatigue, diarrhea) and no sign of pneumonia on thoracic computed tomography (CT) scan. Moderate cases were defined as clinical symptoms associated with dyspnea and radiological findings of pneumonia on thoracic CT scan, and requiring a maximum of 3 L/min of oxygen. Severe cases were defined as respiratory distress requiring more than 3 L/min of oxygen and no other organ failure. Critical cases were defined as respiratory failure requiring mechanical ventilation, shock and/or other organ failure that require an intensive care unit (ICU).

### **Patient characteristics**

Fifty Covid-19 patients and 18 healthy controls were included. The demographic and clinical characteristics of the patients are shown in **Table 1**. The median age of the patients was 55 years (interquartile range, 50 to 63) and 78% were male, while median age of healthy controls was 51 years (interquartile range, 38 to 60) and 72% were male. Patients were analyzed after a median duration of 10 days (interquartile range, 9 to 11) after disease onset. Fever was present in 98% of the patients, and

other most common symptoms were dyspnea (n=49, 98%), fatigue (n=48, 96%), cough (n=46, 92%), myalgia (n=31, 62%) and diarrhea (n=17, 34%). Among the whole population, 44% had at least one controlled coexisting illness, mainly hypertension and type 2 diabetes.

On admission, the degree of severity of Covid-19 was categorized as mild-to-moderate in 15 patients (median oxygen requirement 2 L/min), severe in 17 patients (median oxygen requirement 5 L/min) and critical in 18 patients. Of 46 CT scan available at the time of admission, all were abnormal, showing ground-glass opacities (100%) with bilateral patchy distribution (96%) (**Table 1**). Most of the patients had elevated CRP, ferritin and lactate dehydrogenase (LDH) levels. Patients with severe and critical disease had more prominent laboratory abnormalities than those with mild-to-moderate disease (**Supplementary Figure 1A-C**), and extension on chest CT scan was correlated with disease severity (**Supplementary Figure 1D-E**). No patients with mild-to-moderate disease required admission to an ICU or the use of mechanical ventilation, while 10 out of 17 patients with severe disease were eventually admitted to the ICU (and 5 of them underwent invasive mechanical ventilation).

### **Multiparameter phenotyping of peripheral blood leukocytes using mass cytometry**

The Maxpar<sup>®</sup> Direct<sup>™</sup> Immune Profiling System (Fluidigm, Inc Canada) was used for high-dimensional immune profiling of whole blood, using a 30-marker antibody panel with the addition of two markers: anti-PD1 conjugated to <sup>175</sup>Lu (1 µg/µL concentration) and anti-Tim3 conjugated to <sup>165</sup>Ho (1 µg/µL concentration). The list of antibodies and definition of cellular subsets used is summarized in **Supplementary Table 1**. For each sample, 10 µL of 10 KU/mL heparin solution was added to 1 mL of

whole blood, then the samples were incubated for 20 minutes at room temperature. After incubation, 270  $\mu$ L of heparin treated whole blood was directly added to the dry antibody cocktail and anti-PD1 and anti-Tim3 were added, for an incubation of 30 minutes. Red blood cells were then lysed immediately using CAL-Lyse Lysing Solution (Life Technologies). After a 10-min incubation, 3 mL of MaxPar Water was added to each tube for an additional 10-min incubation. Cells were washed three times using MaxPar Cell Staining Buffer and then fixed for 10 min using with 1.6% paraformaldehyde (Sigma-Aldrich, Lyon, France). Cells were washed once with MaxPar Cell Staining Buffer and incubated one hour in Fix and Perm Buffer with 1:1000 of Iridium intercalator (pentamethylcyclopentadienyl-Ir (III)-dipyridophenazine, Fluidigm, Inc Canada). Cells were washed and resuspended in Maxpar Cell Acquisition Solution, a high-ionic-strength solution, at a concentration of 1 million cells per mL and mixed with 10% of EQ Beads immediately before acquisition.

Cell events were acquired on the Helios mass cytometer and CyTOF software version 6.7.1014 (Fluidigm, Inc Canada) at the "Plateforme de Cytométrie de la Pitié-Salpêtrière (CyPS)." An average of 400,000 events were acquired per sample. Mass cytometry standard files produced by the HELIOS were normalized using the CyTOF Software v. 6.7.1014. This method normalizes the data to a global standard determined for each log of EQ beads.

FCS3.0 files generated by the Helios were analyzed using GemStone software (Verity Software House, Topsham, ME), an automated analysis system. This system is integrated with dimensionality-reduction mapping known as Cauchy Enhanced Nearest-neighbor Stochastic Embedding (Cen-se™), which generates a visual display of high-dimensional data labeled with the major cell populations.

The multiparametric analysis of activation and immune checkpoint markers was performed on FlowJo and the data generated were then analysed using Tableau Desktop. For viSNE analysis (Cytobank Inc, Mountain View, CA, USA), mapping integrating a total of 50,000 PBMC sampled analyzed for each group FCS file. Parameter viSNE maps were created with all markers. The settings used for the viSNE run were as follow: iterations (3000), perplexity (70) and theta (0.5). ViSNE maps are presented as means of all samples in each disease severity category.

### **Gene expression analysis**

Total mRNA were diluted with RNase-free water at 20 ng/μl in 12-strips. We analyzed 100 ng (5 μl) of total RNA from each sample using the Nanostring Human Immunology kit v2 according to manufacturer's instructions. Each sample was analyzed in a separate multiplexed reaction including in each, eight negative probes and six serial concentrations of positive control probes.

Data were imported into nSolver analysis software (version 2.5) for quality checking, then exported as a table, and all subsequent analyses were performed using R version 4.3, using ggplot2 for plots. Background level was computed as mean + 2 standard deviation of the negative control probes, for all samples. The housekeeping genes were selected from the 15 candidate control genes provided by Nanostring, following the geNorm method<sup>2</sup>. Briefly, after selection of genes with all values above the background level, for each two genes  $j \neq k$ , pairwise variation coefficient  $V_{jk}$  is defined as

$$V_{jk} = \text{sd}_i \left( \log_2 \left( \frac{a_{ij}}{a_{ik}} \right) \right),$$

where  $a_{ij}$  is the number of counts for the gene  $j$  in the sample  $i$ . The gene stability measure  $M_j$  for control gene  $j$  is the arithmetic mean of all pairwise variations  $V_{jk}$  for  $k \neq j$ .  $M_j$  evaluates the degree of correlation of gene  $j$  to other control genes (the

smaller  $M_j$  is, the more correlated gene  $j$  is to other control genes). Genes were ranked by increasing  $M$ , and to determine a threshold, the normalization factors  $NF_n$  was computed for all  $n$  (defined as the geometric mean of the housekeeping gene counts) of each sample when considering the  $n$  genes with lowest  $M$  as a housekeeping gene set. Correlations between consecutive normalization factors increased then decreased when adding the 6th gene with lowest  $M$ . This threshold was confirmed by studying the pairwise variation between consecutive  $NF_n$ s. The final housekeeping gene set consisted of the following 5 genes: *TUBB*, *GUSB*, *SDHA*, *TBP*, *ABCF1*. Normalization was performed as follows: the scaling factor for a sample was defined as the ratio of the average across all geometric means and the geometric mean of the sample. For each sample, all gene counts were multiplied by the corresponding scaling factor. After normalization, background level was re-computed as 27 normalized counts. Genes with no values above background levels, as well as positive, negative control and housekeeping genes were removed from subsequent analyses. Normalized counts were  $\log_{10}$ -transformed for all subsequent analyses.

### ***Principal component analysis***

Principal component analysis was performed using *prcomp* (package *stats*) on data centered and scaled to 1 for each gene. Genes were ordered by absolute contribution for each principal component, and then fed to the gene set enrichment algorithm (GSEA version 4.0.3, Broad Institute), along with a pathway data set built from the Nanostring Immunology panel version 2 annotation file. Parameters were set as follows: method, pre-ranked gene list; number of permutations, 2,000; enrichment statistic, classic; min set size, 5; max set size, 200; and all other parameters as default.

### ***Volcano plots***

For each group comparison, genes with at least one value above background levels in one of the groups were tested. *t*-tests, which are shown to be extremely robust against non-normality<sup>3</sup>, were performed to compare groups. *z*-score was defined as

$$z = -\log_{10}(p\text{-value}) \times |\log_2(\text{fold change})|.$$

### ***Heatmaps***

Heatmaps were plotted using pheatmap (package pheatmap), with data centered to 0 and scaled to unit variance for each gene. All genes were plotted in **Figure 2**. For subsequent heatmaps, analysis of variance on severity groups was used to determine *p*-values for each gene, which were corrected by false-discovery rate *q*-values. Only genes with *q*-values < 0.05 (that is, that are differentially expressed in at least one severity group), were plotted in heatmaps of Figure 3 and 4.

### ***Kinetic plots***

Data were centered to 0 and scaled to unit variance for each gene, then average values for each severity grade were plotted (each grey line corresponds to one gene). Black line was median value over genes for each severity grade.

### ***Cytokines assays***

Prior to protein analysis plasma samples were treated in a P3 laboratory for viral decontamination using a protocol previously described for SARS-CoV<sup>4</sup>, which we validated for SARS-CoV2. Briefly, samples were treated with Tri-n-Butyl Phosphate (TnBP) 0.3% (v/v) and TRITON X100 (TX100) 1% (v/v) for 2hrs at RT. After treatment TnBP was removed by passing the samples through a C18 column (Discovery DSC-18 SPE from Supelco). IFN $\alpha$ 2, IFN $\gamma$ , IL-17A, (triplex) and IFN $\beta$  (single plex) protein plasma concentrations were quantified by Simoa assays

developed with Quanterix Homebrew kits as previously described<sup>5</sup>. IL-6, TNF $\alpha$ , and IL-10 were measured with a commercial triplex assay (Quanterix). For the IFN $\alpha$  assay, the BMS216C (eBioscience) antibody clone was used as a capture antibody after coating on paramagnetic beads (0.3mg/mL), and the BMS216BK already biotinylated antibody clone was used as the detector at a concentration of 0.3ug/mL. The SBG revelation enzyme concentration was 150pM. Recombinant IFN $\alpha$ 2c (eBioscience) was used as calibrator. For the IFN $\beta$  assay, the 710322-9 IgG1, kappa, mouse monoclonal antibody (PBL Assay Science) was used as a capture antibody after coating paramagnetic beads (0.3 mg/mL), the 710323-9 IgG1, kappa, mouse monoclonal antibody (PBL Assay Science) was biotinylated (biotin/antibody ratio = 40/1) and used as the detector antibody, and recombinant protein (PBL Assay Science) were used to quantify IFN $\beta$  concentrations. For the IFN $\gamma$  assay, the 507501 antibody clone (BioLegend) was used as a capture antibody after coating on paramagnetic beads (0.3 mg/mL), the MAB285 antibody clone (R&D Systems) was biotinylated (biotin/antibody ratio = 40/1) and used as the detector antibody at a concentration of 0.3ug/mL. The SBG revelation enzyme concentration was 150pM. Recombinant protein (PBL Assay Science) was used to quantify IFN $\gamma$  concentrations. For the IL17A assay, the 512702 antibody clone (BioLegend) was used as a capture antibody after coating on paramagnetic beads (0.3 mg/mL), the MT504 antibody clone (MabTech), already biotinylated, was used as the detector antibody at a concentration of 0.3ug/mL. The SBG revelation enzyme concentration was 150pM. The limit of detection (LOD) of these assays were 0.6 pg/mL for IFN- $\beta$ , 2 fg/mL for IFN- $\alpha$ , 7 fg/mL for IFN- $\gamma$  and 3 pg/mL for IL17A including the dilution factor. Additional plasma cytokines and chemokines were measured with a commercial Luminex multi-analyte assay (Biotechne, R&D systems).

RIPK3 plasma levels were measured using an ELISA kit (CSB-EL019737HU, CUSABIO) and following the manufacturer's instructions.

### **Type I interferon activity**

Type I IFN activity was measured as previously described<sup>6</sup> by determining the cytopathic reduction (i.e., protection of Madin–Darby bovine kidney cells against cell death after infection with vesicular stomatitis virus) afforded by patient serum. A reference of human IFN $\alpha$ , standardized against the National Institutes of Health reference Ga 023–902-530, was included with each titration. IFN- $\alpha$  activity in normal healthy serum is <2 IU/ml.

### **Assessment of ISG expression in blood cells**

Total RNA was extracted using a RNA isolation kit. RNA concentration was assessed using a spectrophotometer (NanoDrop UV Visible Spectrophotometer, Thermofischer). Quantitative reverse transcription polymerase chain reaction (qPCR) analysis was performed using the TaqMan Universal PCR Master Mix (Applied Biosystems) and cDNA derived from 40ng total RNA. Using TaqMan probes for *IFI27* (Hs01086370\_m1), *IFI44L* (Hs00199115\_m1), *IFIT1* (Hs00356631\_g1), *ISG15* (Hs00192713\_m1), *RSAD2* (Hs01057264\_m1), and *SIGLEC1* (Hs00988063\_m1), the relative abundance of each target transcript was normalized to the expression level of *GAPDH* (Hs03929097\_g1). Real Time quantitative PCR was performed in duplicate using the LightCycler VIIA7 System (Roche). The RQ value was equal to  $2^{\Delta\Delta Ct}$  where  $\Delta\Delta Ct$  is calculated by (CT target-CT GAPDH) test sample -(CT target-CT GAPDH) calibrator sample. ISG score was considered as the mean of the genes used to assess type I IFN.

### **Quantification of plasma viral load**

SARS-CoV-2 viremia was quantified in each patient blood samples using the Naica™ droplet based digital PCR machine Stilla<sup>Inc</sup> (Villejuif, France) with COVID-19 Multiplex Crystal digital PCR detection kit (Apexbio<sup>Inc</sup>, Beijing, China). Plasma viral RNA was extracted using QIAamp® Viral RNA Mini Kit following the manufacturer guidelines. Results were automatically analyzed using "Crystal reader" and "Crystal Miner" software and SARS CoV-2 viral concentration (cp/mL) were finally calculated considering the extracted volume of plasma (140 µL).

### **Statistical analysis**

GraphPad Prism was used for statistical analysis. P values were determined by a Kruskal-Wallis test, followed by Dunn's post-test for multiple group comparisons with median reported; \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001. Correlations between the different assays were calculated using Spearman test.

### **Supplementary references**

1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020;
2. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol* 2002;3(7):RESEARCH0034.
3. Rasch D, Teuscher F, Guiard V. How robust are tests for two independent samples? *J Stat Plan Inference* 2007;137(8):2706–20.
4. Darnell MER, Taylor DR. Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products. *Transfusion (Paris)* 2006;46(10):1770–7.
5. Rodero MP, Decalf J, Bondet V, et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease. *J Exp Med* 2017;214(5):1547–55.
6. Lebon P, Ponsot G, Aicardi J, Goutières F, Arthuis M. Early intrathecal synthesis of interferon in herpes encephalitis. *Biomed Publiee Pour AAICIG* 1979;31(9–10):267–71.

**Supplementary Table 1. Phenotypic definition of immune cell populations.**

<b>CD8+ T cells</b>	CD3+ CD66b- CD19- CD8+ CD4- CD14- CD161-TCR $\gamma\delta$ - CD123- CD11c-
<b>CD8 differentiation stages</b>	
<i>Naive</i>	CCR7+ CD27+ CD45RA+
<i>Central memory</i>	CCR7+ CD27+ CD45RA-
<i>Effector memory</i>	CCR7- CD27+
<i>Terminal effector</i>	CCR7- CD27-
<b>CD4+ T cells</b>	CD3+ CD66b- CD19- CD8- CD4+ CD14- CD161- TCR $\gamma\delta$ - CD123- CD11c
<b>CD4 differentiation stages</b>	
<i>Naive</i>	CCR7+ CD27+ CD45RA+
<i>Central memory</i>	CCR7+ CD27+ CD45RA-
<i>Effector memory</i>	CCR7- CD27+ CD45RA-
<i>Terminal effector</i>	CCR7- CD27- CD45RA-
<b>CD4 polarization stages</b>	
<i>Th1</i>	CXCR3+ CCR6- CCR4- CXCR5-
<i>Th2</i>	CXCR3- CCR6- CCR4+ CXCR5-
<i>Th17</i>	CXCR3- CCR6+ CCR4+ CXCR5-
<i>Regulatory T cells</i>	CD25+ CD127- CCR4+ HLA-DR-
<b><math>\gamma\delta</math> T cells</b>	CD3+ CD66b- CD14- CD8dim CD4- TCR $\gamma\delta$ +
<b>Natural killer (NK) cells</b>	CD14- CD3- CD123- CD66b- CD45RA+ CD56+
<b>Mucosal-associated invariant T (MAIT) and NKT cells</b>	CD3+ CD66b- CD19- CD4- CD14- CD161+ TCR $\gamma\delta$ - CD28+ CD16-
<b>B cells</b>	CD3- CD14- CD56- CD16- CD19+ CD20+ HLA-DR+
<b>Plasmablasts</b>	CD3- CD14- CD16- CD66b- CD20- CD19+ CD56- CD38++ CD27++
<b>Dendritic cells (DC)</b>	
pDC	CD3- CD19- CD14- CD20- CD66b- HLA-DR+ CD11c- CD123+
mDC	CD3- CD19- CD14- CD20- HLA-DR+ CD11c+ CD123- CD16- CD38+ CD294-
<b>Monocytes</b>	CD3- CD19- CD56- CD66b- CD14+ HLA-DR+ CD11c+
<i>Classical</i>	CD14+ CD38+
<i>Transitional</i>	CD14 <sup>low</sup> CD38 <sup>low</sup>
<i>Non-classical</i>	CD14- CD38-
<b>Neutrophils</b>	CD66b+ CD16+ HLA-DR-

### **Supplementary Figure legends**

**Supplementary Figure 1. Laboratory and lung imaging findings in patients with Covid-19 according to disease severity.** (A-C) C-reactive protein (CRP), ferritin and lactate dehydrogenase (LDH) from patients with Covid-19 according to disease severity. (D) Degree of extension of lung involvement assessed on chest CT scan according to disease severity. (E) Coronal window images from chest CT scan from patients with various degrees of lung involvement consisting of ground-glass opacities and areas of consolidation. P values were determined by the Kruskal-Wallis test, followed by Dunn's post-test for multiple group comparisons with median reported; \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.

**Supplementary Figure 2. Differentiation of CD4+ and CD8+ T cells in patients with SARS-CoV-2 infection.** (A) Gating strategy for the analysis of differentiation of CD4+ and CD8+ T cells by mass cytometry, based on the expression of CD45RA and CCR7. Illustrative dot plots are shown of CD4+ and CD8+ T cells and enumeration of percentages of each differentiation stage. (B) Proportions (frequencies) of each stage of T cell differentiation, - naïve, central memory (TCM), effector memory (TEM), terminally differentiated (or TEMRA), and naive/memory ratio. P values were determined by the Kruskal-Wallis test, followed by Dunn's post-test for multiple group comparisons with median reported; \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.

**Supplementary Figure 3. CD4+ T cell polarization and minor T cells subsets in patients with SARS-CoV-2 infection.**

**(A)** Proportions (frequencies) of each T helper cells subsets, based on the expression of CXCR3, CCR6, CXCR5, CCR4, CD25 and CD127. Th1 cells are defined as CXCR3<sup>+</sup> CCR6<sup>-</sup> CXCR5<sup>-</sup> CD4<sup>+</sup> T cells; Th2 cells as CXCR3<sup>-</sup> CCR6<sup>-</sup> CXCR5<sup>-</sup> CCR4<sup>+</sup> CD4<sup>+</sup> T cells; Th17 cells as CXCR3<sup>-</sup> CCR6<sup>+</sup> CXCR5<sup>-</sup> CCR4<sup>+</sup> CD4<sup>+</sup> T cells; and regulatory T cells as CD25<sup>+</sup> CD127<sup>-</sup> CCR4<sup>+</sup> CD4<sup>+</sup> T cells. **(B)** Proportions (frequencies) of minor T cells subsets. MAIT and NKT cells are defined as CD4<sup>-</sup> CD14<sup>-</sup> CD161<sup>+</sup> TCR $\gamma\delta$ <sup>-</sup> CD16<sup>-</sup> CD28<sup>+</sup> CD3<sup>+</sup> T cells. T $\gamma\delta$  cells are defined as CD8dim CD4<sup>-</sup> CD14<sup>-</sup> TCR $\gamma\delta$ <sup>+</sup> CD3<sup>+</sup> T cells. P values were determined by the Kruskal-Wallis test, followed by Dunn's post-test for multiple group comparisons with median reported; \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.

**Supplementary Figure 4. Expression of genes associated with B cell activation and plasmablast differentiation.**

Absolute RNA count using Nanostring nCounter technology and showing increased expression of *IL4R*, *TNFSF13B* and *XBP1* transcripts in patients with mild-to-moderate (n=11), severe (n=10) and critical (n=11) patients with SARS-CoV2 infection, and 13 healthy controls. P values were determined by the Kruskal-Wallis test, followed by Dunn's post-test for multiple group comparisons with median reported; \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.

**Supplementary Figure 5. Activation status of lymphocyte subsets.**

**(A)** viSNE map colored by the expression of specific markers (Tim-3, PD-1, HLA-DR and CD38) across disease severity. Red color represents the highest expression of the marker and dark blue the lowest expression. **(B)** Gating strategy for the analysis of activation and exhaustion markers of CD4<sup>+</sup> and CD8<sup>+</sup> T cells by mass cytometry,

based on the expression of CD38, HLA-DR and PD-1. Illustrative dot plots are shown of CD4<sup>+</sup> and CD8<sup>+</sup> T cells and enumeration of percentages of positive cells.

**(C)** Absolute RNA count using Nanostring nCounter technology and showing increased expression of *BATF*, *IRF4* and *CD274* transcripts in patients with mild-to-moderate (n=11), severe (n=10) and critical (n=11) patients with SARS-CoV2 infection, and 13 healthy controls. P values were determined by the Kruskal-Wallis test, followed by Dunn's post-test for multiple group comparisons with median reported; \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.

### **Supplementary Figure 6. T cell apoptosis in patients with SARS-CoV-2 infection.**

**(A)** Left: a representative flow cytometry analysis of Annexin V and Zombie (viability marker) in CD4<sup>+</sup> and CD8<sup>+</sup> T cells from a control and from a critically ill patient. Right: Annexin V<sup>+</sup> Zombie<sup>-</sup> CD4<sup>+</sup> and CD8<sup>+</sup> T cells (as a percentage of total CD4<sup>+</sup> T cells) in the peripheral blood of HCs and patients according to disease severity. **(B)** Heatmap showing expression of apoptosis-related gene using the Nanostring nCounter technology in patients with mild-to-moderate (n=11), severe (n=10) and critical (n=11) patients with SARS-CoV2 infection, and 13 healthy controls (no disease). Up-regulated genes are shown in red and down-regulated genes in blue. P values were determined by the Kruskal-Wallis test, followed by Dunn's post-test for multiple group comparisons with median reported; \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.

### **Supplementary Figure 7. Expression of interferon type I stimulated genes (ISGs) in blood cells from patients with SARS-CoV-2 infection.**

**(A)** Expression of 6 ISGs (*IFI44L*, *IFI27*, *RSAD2*, *SIGLEC1*, *IFIT1* and *IS15*) measured by q-RT-PCR in whole blood cells from mild-to-moderate (n=14), severe (n=15) and critical (n=17) patients, and 18 healthy controls (No disease). Results represent the fold-increased expression compared to the mean of unstimulated controls and are normalized to *GAPDH*. **(B)** Correlation between ISG score and IFN- $\alpha$ 2 concentration in plasma from all patients and controls.

**Supplementary Figure 8. Characterization of the cytokine storm.**

**(A)** *Left panel* represents genes involved in innate immunity pathway whereas *right panel* represents genes involved in cytokine and chemokine signalling visualised as kinetics plots showing mean normalized value for each gene and severity grade (each grey line corresponds to one gene belonging to the respective pathways). Median values over genes for each severity grade were plotted in black. **(B)** RNA count for genes involved in IL-6 signaling; *from left to right*; *IL6*, *IL6R*, *SOCS3* and *STAT3*. **(C)** RNA count for *TNF* gene, encoding for TNF $\alpha$  protein, and **(D)** RNA count for *TNFSF10* gene, encoding for TRAIL protein. **(E)** Heatmap showing the expression of TNF pathway related genes ordered by hierarchical clustering. Up-regulated genes are shown in red and down-regulated genes in blue. **(F)** *Left panel*; RNA count for *IL1B* gene, middle panel shows RNA count for *IL1R1* gene, right panel represent plasma protein quantification for IL1 receptor antagonist (IL1RA) by luminex technology. **(G)** RNA count for *IL10* gene. Dashed line depicts LOD. RNA data are extracted from the Nanostring nCounter analysis (see methods). No diseases (n=13), mild-to-moderate (n=11), severe (n=10) and critical (n=11). P values were determined by the Kruskal-Wallis test, followed by Dunn's post-test for multiple group comparisons with median reported; \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.

**Supplementary Figure 9. Cytokines related to Th1 and Th17 immunity.**

Interferon (IFN)- $\gamma$  (left panel) and IL-17 (right panel) were measured in the plasma using the simoa digital Elisa. P values were determined by the Kruskal-Wallis test, followed by Dunn's post-test for multiple group comparisons with median reported; \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.

**Supplementary Figure 10. The cytokine storm is driven by NF $\kappa$ B activation.**

**(A)** Heatmap showing the expression of genes related to transcriptional regulation and ordered by hierarchical clustering. Up-regulated genes are shown in red and down-regulated genes in blue. No diseases (n=13), mild-to-moderate (n=11), severe (n=10) and critical (n=11). **(B)** RNA count for genes regulating NF $\kappa$ B activation. *NFKB1* and *NFKB2* encode subunits of NF $\kappa$ B transcriptional factor. *IKBKG* encodes NEMO protein. RNA data are extracted from the Nanostring nCounter analysis (see methods). No diseases (n=13), mild-to-moderate (n=11), severe (n=10) and critical (n=11). P values were determined by the Kruskal-Wallis test, followed by Dunn's post-test for multiple group comparisons with median reported; \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001.